Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis
While covalent Bruton's tyrosine kinase inhibitors (cBTKis) have become a standard of care treatment for relapsed/refractory mantle cell lymphoma (R/R MCL), response duration is limited and resistance to BTKi and/or adverse events develop in a subset of patients. However, little real-world evid...
Saved in:
Published in: | Clinical lymphoma, myeloma and leukemia Vol. 24; no. 10; pp. e350 - e358.e1 |
---|---|
Main Authors: | , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
Elsevier Inc
01-10-2024
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | While covalent Bruton's tyrosine kinase inhibitors (cBTKis) have become a standard of care treatment for relapsed/refractory mantle cell lymphoma (R/R MCL), response duration is limited and resistance to BTKi and/or adverse events develop in a subset of patients. However, little real-world evidence on post-cBTKi clinical and economic outcomes exists for these patients.
This retrospective study used 2010 to 2019 U.S. Medicare claims, to identify elderly (≥ 66 years) patients with newly-diagnosed MCL who received third-line (3L) treatment and had evidence of cBTKi use in a prior line of therapy. Outcomes were assessed ≥ 12-months post 3L-treatment initiation and included treatment patterns, all-cause and MCL-related HRU and costs, and overall survival.
The final sample contained 230 elderly patients with R/R MCL receiving 3L treatment who had cBTKi use in a prior line of therapy (mean age 75.0, 21.7% age > 80 years; 67.4% male; 93.9% White). Common 3L treatments included chemotherapy (26.1%), lenalidomide (18.7%), and bortezomib (18.3%); 1-quarter (25.7%) of patients received a cBTKi (17.8% ibrutinib; 7.8% acalabrutinib). Overall survival was poor from 3L treatment initiation (median OS = 9.4 months; 1-years survival rate = 43.7%). Patients exhibited high rates of HRU (73.6% experienced hospitalization) and substantial costs ($145,726) in the 12-months after 3L initiation.
A large unmet need exists in this patient subpopulation, highlighting the importance of ongoing development of novel therapeutics.
Treating older adults with relapsed mantle cell lymphoma (MCL) beyond Bruton tyrosine kinase inhibitors may be challenging. We conducted a real-world study of 3L + MCL therapy using 100% Medicare claims and found limited treatment options. Survival was poor and healthcare costs were high. These findings confirm a large unmet need and highlight the importance of ongoing development of novel therapeutics. |
---|---|
AbstractList | While covalent Bruton's tyrosine kinase inhibitors (cBTKis) have become a standard of care treatment for relapsed/refractory mantle cell lymphoma (R/R MCL), response duration is limited and resistance to BTKi and/or adverse events develop in a subset of patients. However, little real-world evidence on post-cBTKi clinical and economic outcomes exists for these patients.
This retrospective study used 2010 to 2019 U.S. Medicare claims, to identify elderly (≥ 66 years) patients with newly-diagnosed MCL who received third-line (3L) treatment and had evidence of cBTKi use in a prior line of therapy. Outcomes were assessed ≥ 12-months post 3L-treatment initiation and included treatment patterns, all-cause and MCL-related HRU and costs, and overall survival.
The final sample contained 230 elderly patients with R/R MCL receiving 3L treatment who had cBTKi use in a prior line of therapy (mean age 75.0, 21.7% age > 80 years; 67.4% male; 93.9% White). Common 3L treatments included chemotherapy (26.1%), lenalidomide (18.7%), and bortezomib (18.3%); 1-quarter (25.7%) of patients received a cBTKi (17.8% ibrutinib; 7.8% acalabrutinib). Overall survival was poor from 3L treatment initiation (median OS = 9.4 months; 1-years survival rate = 43.7%). Patients exhibited high rates of HRU (73.6% experienced hospitalization) and substantial costs ($145,726) in the 12-months after 3L initiation.
A large unmet need exists in this patient subpopulation, highlighting the importance of ongoing development of novel therapeutics. While covalent Bruton's tyrosine kinase inhibitors (cBTKis) have become a standard of care treatment for relapsed/refractory mantle cell lymphoma (R/R MCL), response duration is limited and resistance to BTKi and/or adverse events develop in a subset of patients. However, little real-world evidence on post-cBTKi clinical and economic outcomes exists for these patients.BACKGROUNDWhile covalent Bruton's tyrosine kinase inhibitors (cBTKis) have become a standard of care treatment for relapsed/refractory mantle cell lymphoma (R/R MCL), response duration is limited and resistance to BTKi and/or adverse events develop in a subset of patients. However, little real-world evidence on post-cBTKi clinical and economic outcomes exists for these patients.This retrospective study used 2010 to 2019 U.S. Medicare claims, to identify elderly (≥ 66 years) patients with newly-diagnosed MCL who received third-line (3L) treatment and had evidence of cBTKi use in a prior line of therapy. Outcomes were assessed ≥ 12-months post 3L-treatment initiation and included treatment patterns, all-cause and MCL-related HRU and costs, and overall survival.PATIENTS AND METHODSThis retrospective study used 2010 to 2019 U.S. Medicare claims, to identify elderly (≥ 66 years) patients with newly-diagnosed MCL who received third-line (3L) treatment and had evidence of cBTKi use in a prior line of therapy. Outcomes were assessed ≥ 12-months post 3L-treatment initiation and included treatment patterns, all-cause and MCL-related HRU and costs, and overall survival.The final sample contained 230 elderly patients with R/R MCL receiving 3L treatment who had cBTKi use in a prior line of therapy (mean age 75.0, 21.7% age > 80 years; 67.4% male; 93.9% White). Common 3L treatments included chemotherapy (26.1%), lenalidomide (18.7%), and bortezomib (18.3%); 1-quarter (25.7%) of patients received a cBTKi (17.8% ibrutinib; 7.8% acalabrutinib). Overall survival was poor from 3L treatment initiation (median OS = 9.4 months; 1-years survival rate = 43.7%). Patients exhibited high rates of HRU (73.6% experienced hospitalization) and substantial costs ($145,726) in the 12-months after 3L initiation.RESULTSThe final sample contained 230 elderly patients with R/R MCL receiving 3L treatment who had cBTKi use in a prior line of therapy (mean age 75.0, 21.7% age > 80 years; 67.4% male; 93.9% White). Common 3L treatments included chemotherapy (26.1%), lenalidomide (18.7%), and bortezomib (18.3%); 1-quarter (25.7%) of patients received a cBTKi (17.8% ibrutinib; 7.8% acalabrutinib). Overall survival was poor from 3L treatment initiation (median OS = 9.4 months; 1-years survival rate = 43.7%). Patients exhibited high rates of HRU (73.6% experienced hospitalization) and substantial costs ($145,726) in the 12-months after 3L initiation.A large unmet need exists in this patient subpopulation, highlighting the importance of ongoing development of novel therapeutics.CONCLUSIONA large unmet need exists in this patient subpopulation, highlighting the importance of ongoing development of novel therapeutics. While covalent Bruton's tyrosine kinase inhibitors (cBTKis) have become a standard of care treatment for relapsed/refractory mantle cell lymphoma (R/R MCL), response duration is limited and resistance to BTKi and/or adverse events develop in a subset of patients. However, little real-world evidence on post-cBTKi clinical and economic outcomes exists for these patients. This retrospective study used 2010 to 2019 U.S. Medicare claims, to identify elderly (≥ 66 years) patients with newly-diagnosed MCL who received third-line (3L) treatment and had evidence of cBTKi use in a prior line of therapy. Outcomes were assessed ≥ 12-months post 3L-treatment initiation and included treatment patterns, all-cause and MCL-related HRU and costs, and overall survival. The final sample contained 230 elderly patients with R/R MCL receiving 3L treatment who had cBTKi use in a prior line of therapy (mean age 75.0, 21.7% age > 80 years; 67.4% male; 93.9% White). Common 3L treatments included chemotherapy (26.1%), lenalidomide (18.7%), and bortezomib (18.3%); 1-quarter (25.7%) of patients received a cBTKi (17.8% ibrutinib; 7.8% acalabrutinib). Overall survival was poor from 3L treatment initiation (median OS = 9.4 months; 1-years survival rate = 43.7%). Patients exhibited high rates of HRU (73.6% experienced hospitalization) and substantial costs ($145,726) in the 12-months after 3L initiation. A large unmet need exists in this patient subpopulation, highlighting the importance of ongoing development of novel therapeutics. Treating older adults with relapsed mantle cell lymphoma (MCL) beyond Bruton tyrosine kinase inhibitors may be challenging. We conducted a real-world study of 3L + MCL therapy using 100% Medicare claims and found limited treatment options. Survival was poor and healthcare costs were high. These findings confirm a large unmet need and highlight the importance of ongoing development of novel therapeutics. |
Author | Kamal-Bahl, Sachin Raut, Monika Doshi, Jalpa Huntington, Scott F. Puckett, Justin Ryland, Katherine Elizabeth Squires, Patrick |
Author_xml | – sequence: 1 givenname: Patrick surname: Squires fullname: Squires, Patrick organization: Merck & Co, Inc, Rahway, NJ – sequence: 2 givenname: Justin orcidid: 0000-0002-5135-7216 surname: Puckett fullname: Puckett, Justin email: justin@coviahealthsolutions.com organization: COVIA Health Solutions, Lansdale, PA – sequence: 3 givenname: Katherine Elizabeth orcidid: 0009-0001-1749-7880 surname: Ryland fullname: Ryland, Katherine Elizabeth organization: Merck & Co, Inc, Rahway, NJ – sequence: 4 givenname: Sachin surname: Kamal-Bahl fullname: Kamal-Bahl, Sachin email: sachin@coviahealthsolutions.com organization: COVIA Health Solutions, Lansdale, PA – sequence: 5 givenname: Monika surname: Raut fullname: Raut, Monika organization: Merck & Co, Inc, Rahway, NJ – sequence: 6 givenname: Jalpa surname: Doshi fullname: Doshi, Jalpa organization: Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA – sequence: 7 givenname: Scott F. surname: Huntington fullname: Huntington, Scott F. organization: Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39034204$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kE1v1DAQhi3Uin7AH-CAfOTQhLGdbDYSl3a1fIitqGBRj5ZjT8Arx27tJFL_fb1s6bEnj6z3fTTznJEjHzwS8o5ByYAtPu5K7QZXcuBVCXUJXLwip5zVvOCLRXv0PNdwQs5S2gE0AKx9TU5EC6LiUJ2S-ScqV9yG6AzdRlTjgH6kN2ocMfp0QX9NcbazchdUeUPXOvgwWE2vpmjQ08sh-D907QxG90CvV5t902ZCojcRZxumlP__cdHQWzv-pfpq-92mN-S4Vy7h26f3nPz-vN6uvhabH1--rS43heaiGYuOCYMtArRC9IhYMawVE7oxS64XrarVEuuuY7zSgA1wBU2LnTL9kve9Mkackw8H7l0M9xOmUQ42aXROeczLSQFLkS01Lc9RfojqGFKK2Mu7aAcVHyQDufctd3LvW-59S6hl9p1L75_4Uzegea78F5wDnw4BzFfOFqNMOgvSaGxEPUoT7Ev8RwgulFE |
Cites_doi | 10.1111/bjh.15567 10.1111/bjh.16922 10.1016/j.jgo.2020.12.013 10.1002/ajh.26109 10.1111/bjh.18519 10.1016/S0140-6736(15)00667-4 10.1097/PPO.0000000000000412 10.2147/OTT.S155778 10.1080/10428194.2021.1919662 10.1182/blood-2015-03-635326 10.2147/BLCTT.S426588 10.6004/jnccn.2021.0054 10.1016/j.clinthera.2021.06.012 10.1007/s11912-022-01272-6 10.1200/JCO.2008.19.6121 10.1002/cam4.2565 10.1016/S0140-6736(21)00224-5 10.1158/1078-0432.CCR-19-3703 10.1002/ajh.26306 10.1056/NEJMoa1200920 10.1186/s13045-016-0313-y 10.1182/bloodadvances.2022007247 10.1056/NEJMoa1306220 10.1002/cncr.23608 10.1080/10428194.2023.2234525 10.21873/anticanres.14846 10.1002/cam4.2268 10.1038/s41375-019-0575-9 10.3390/jpm11080764 10.1016/j.jacep.2018.06.004 10.3390/cancers12051328 10.1080/10428194.2018.1509320 10.1182/blood.2019852368 |
ContentType | Journal Article |
Copyright | 2024 Copyright © 2024. Published by Elsevier Inc. |
Copyright_xml | – notice: 2024 – notice: Copyright © 2024. Published by Elsevier Inc. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1016/j.clml.2024.05.023 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2152-2669 |
EndPage | e358.e1 |
ExternalDocumentID | 10_1016_j_clml_2024_05_023 39034204 S215226502400226X |
Genre | Journal Article |
GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1P~ 1~. 4.4 457 4G. 53G 5VS 6PF 7-5 8P~ AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAWTL AAXKI AAXUO ABBQC ABMAC ABMZM ABXDB ACDAQ ACGFS ACRLP ADBBV ADEZE ADMUD AEBSH AEKER AENEX AEVXI AFCTW AFJKZ AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AXJTR BKOJK BLXMC BNPGV C45 CAG COF DU5 EBS EFJIC EJD EMB EMOBN F5P FDB FEDTE FIRID FNPLU FYGXN GBLVA HVGLF HZ~ KOM M41 MET MO0 O-L O9- OAUVE OC~ OO- OVD P-8 P-9 PC. Q38 ROL SDF SEL SES SPCBC SSH SSZ SV3 T5K TEORI XH2 Z5R ~G- CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c237t-b13de9e00933feee41e5a13c7d82c69a5a8e5bb124c0e702a079ebadf82ffadd3 |
ISSN | 2152-2650 2152-2669 |
IngestDate | Sat Oct 26 03:55:06 EDT 2024 Wed Oct 30 12:35:32 EDT 2024 Sat Nov 02 12:22:48 EDT 2024 Sat Oct 26 15:42:11 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Keywords | Costs Unmet need Medicare Ibrutinib Mantle cell lymphoma |
Language | English |
License | Copyright © 2024. Published by Elsevier Inc. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c237t-b13de9e00933feee41e5a13c7d82c69a5a8e5bb124c0e702a079ebadf82ffadd3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0009-0001-1749-7880 0000-0002-5135-7216 |
PMID | 39034204 |
PQID | 3083215792 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_3083215792 crossref_primary_10_1016_j_clml_2024_05_023 pubmed_primary_39034204 elsevier_sciencedirect_doi_10_1016_j_clml_2024_05_023 |
PublicationCentury | 2000 |
PublicationDate | October 2024 2024-Oct 2024-10-00 20241001 |
PublicationDateYYYYMMDD | 2024-10-01 |
PublicationDate_xml | – month: 10 year: 2024 text: October 2024 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Clinical lymphoma, myeloma and leukemia |
PublicationTitleAlternate | Clin Lymphoma Myeloma Leuk |
PublicationYear | 2024 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Squires, Puckett, Ryland (bib0030) 2023; 64 Zhou, Wang, Fang (bib0002) 2008; 113 Alsuhebany, Pan, Holovac, Do, McBride (bib0017) 2023; 13 Wang, Blum, Martin (bib0013) 2015; 126 Karmali, Switchenko, Goyal (bib0005) 2021; 96 Martin, Chadburn, Christos (bib0006) 2009; 27 Mato, Shah, Jurczak (bib0023) 2021; 397 Dreyling, Jurczak, Jerkeman (bib0008) 2016; 387 Ganatra, Sharma, Shah (bib0012) 2018; 4 Jain, Kanagal-Shamanna, Zhang (bib0034) 2021; 96 Shouse, Danilov, Artz (bib0021) 2022; 24 Weaver, Peng, Ji, Gilbertson, Pease, Morrison (bib0028) 2021; 12 Song, Zhou, Zou (bib0009) 2020; 26 Wang, Rule, Zinzani (bib0018) 2019; 33 Burger (bib0015) 2019; 25 Jeon, Yoon, Min (bib0019) 2019; 8 Mantle Cell Lymphoma. Lymphoma Research Foundation. Accessed November 28, 2022. Narkhede, Goyal, Shea, Mehta, Giri (bib0033) 2022; 6 Wang, Rule, Martin (bib0007) 2013; 369 Girard, Reneau, Devata (bib0011) 2019; 12 Sharman, Kabadi, Clark, Andorsky (bib0004) 2021; 192 Goyal, Jain, Nagar (bib0029) 2021; 62 Witzig, Inwards (bib0010) 2019; 133 SAS: Analytics, Artificial intelligence and data management | SAS. Accessed November 30, 2022. Jain, Kanagal-Shamanna, Zhang (bib0020) 2018; 183 Kluin-Nelemans, Hoster, Hermine (bib0003) 2012; 367 Ghosh, Emond, Lafeuille, Côté-Sergent, Lefebvre, Huang (bib0025) 2021; 43 Goyal, Nagar, Kabadi, Kaye, Seal, Mato (bib0026) 2019; 60 Kabadi, Goyal, Nagar, Kaye, Davis (bib0024) 2019; 8 Kabadi, Byfield, Le, Olufade (bib0027) 2021; 41 George, Mullick Chowdhury, Hart (bib0016) 2020; 12 Zelenetz, Gordon, Chang (bib0031) 2021; 19 Hess, Dreyling, Oberic (bib0035) 2023; 202 Wu, Liu, Tsui, Liu (bib0014) 2016; 9 Lewis, Cheah (bib0022) 2021; 11 Karmali (10.1016/j.clml.2024.05.023_bib0005) 2021; 96 Goyal (10.1016/j.clml.2024.05.023_bib0026) 2019; 60 Squires (10.1016/j.clml.2024.05.023_bib0030) 2023; 64 Zhou (10.1016/j.clml.2024.05.023_bib0002) 2008; 113 Dreyling (10.1016/j.clml.2024.05.023_bib0008) 2016; 387 George (10.1016/j.clml.2024.05.023_bib0016) 2020; 12 Sharman (10.1016/j.clml.2024.05.023_bib0004) 2021; 192 Wang (10.1016/j.clml.2024.05.023_bib0018) 2019; 33 Jeon (10.1016/j.clml.2024.05.023_bib0019) 2019; 8 Jain (10.1016/j.clml.2024.05.023_bib0034) 2021; 96 10.1016/j.clml.2024.05.023_bib0032 Kabadi (10.1016/j.clml.2024.05.023_bib0024) 2019; 8 Witzig (10.1016/j.clml.2024.05.023_bib0010) 2019; 133 Burger (10.1016/j.clml.2024.05.023_bib0015) 2019; 25 Wang (10.1016/j.clml.2024.05.023_bib0007) 2013; 369 Jain (10.1016/j.clml.2024.05.023_bib0020) 2018; 183 Lewis (10.1016/j.clml.2024.05.023_bib0022) 2021; 11 Shouse (10.1016/j.clml.2024.05.023_bib0021) 2022; 24 Martin (10.1016/j.clml.2024.05.023_bib0006) 2009; 27 Mato (10.1016/j.clml.2024.05.023_bib0023) 2021; 397 Goyal (10.1016/j.clml.2024.05.023_bib0029) 2021; 62 Girard (10.1016/j.clml.2024.05.023_bib0011) 2019; 12 Weaver (10.1016/j.clml.2024.05.023_bib0028) 2021; 12 Kluin-Nelemans (10.1016/j.clml.2024.05.023_bib0003) 2012; 367 Wu (10.1016/j.clml.2024.05.023_bib0014) 2016; 9 Alsuhebany (10.1016/j.clml.2024.05.023_bib0017) 2023; 13 10.1016/j.clml.2024.05.023_bib0001 Zelenetz (10.1016/j.clml.2024.05.023_bib0031) 2021; 19 Kabadi (10.1016/j.clml.2024.05.023_bib0027) 2021; 41 Ghosh (10.1016/j.clml.2024.05.023_bib0025) 2021; 43 Wang (10.1016/j.clml.2024.05.023_bib0013) 2015; 126 Song (10.1016/j.clml.2024.05.023_bib0009) 2020; 26 Narkhede (10.1016/j.clml.2024.05.023_bib0033) 2022; 6 Hess (10.1016/j.clml.2024.05.023_bib0035) 2023; 202 Ganatra (10.1016/j.clml.2024.05.023_bib0012) 2018; 4 |
References_xml | – volume: 8 start-page: 6860 year: 2019 end-page: 6870 ident: bib0019 article-title: Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience publication-title: Cancer Med contributor: fullname: Min – volume: 41 start-page: 927 year: 2021 end-page: 936 ident: bib0027 article-title: Adverse events and economic burden among patients receiving systemic treatment for mantle cell lymphoma: a real-world retrospective cohort study publication-title: Anticancer Res contributor: fullname: Olufade – volume: 62 start-page: 1325 year: 2021 end-page: 1334 ident: bib0029 article-title: Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma publication-title: Leuk Lymphoma contributor: fullname: Nagar – volume: 12 start-page: 1328 year: 2020 ident: bib0016 article-title: Ibrutinib resistance mechanisms and treatment strategies for B-cell lymphomas publication-title: Cancers contributor: fullname: Hart – volume: 397 start-page: 892 year: 2021 end-page: 901 ident: bib0023 article-title: Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study publication-title: Lancet Lond Engl contributor: fullname: Jurczak – volume: 183 start-page: 578 year: 2018 end-page: 587 ident: bib0020 article-title: Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib publication-title: Br J Haematol contributor: fullname: Zhang – volume: 202 start-page: 749 year: 2023 end-page: 759 ident: bib0035 article-title: Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study publication-title: Br J Haematol contributor: fullname: Oberic – volume: 24 start-page: 1189 year: 2022 end-page: 1199 ident: bib0021 article-title: CAR T-cell therapy in the older person: indications and risks publication-title: Curr Oncol Rep contributor: fullname: Artz – volume: 96 start-page: E137 year: 2021 end-page: E140 ident: bib0034 article-title: Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib publication-title: Am J Hematol contributor: fullname: Zhang – volume: 387 start-page: 770 year: 2016 end-page: 778 ident: bib0008 article-title: Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study publication-title: Lancet Lond Engl contributor: fullname: Jerkeman – volume: 33 start-page: 2762 year: 2019 end-page: 2766 ident: bib0018 article-title: Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma publication-title: Leukemia contributor: fullname: Zinzani – volume: 133 start-page: 2570 year: 2019 end-page: 2574 ident: bib0010 article-title: Acalabrutinib for mantle cell lymphoma publication-title: Blood contributor: fullname: Inwards – volume: 6 start-page: 4122 year: 2022 end-page: 4131 ident: bib0033 article-title: Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma publication-title: Blood Adv contributor: fullname: Giri – volume: 43 start-page: 1285 year: 2021 end-page: 1299 ident: bib0025 article-title: Treatment patterns among patients with mantle cell lymphoma and comparison of healthcare resource utilization and costs among relapsed/refractory patients treated with ibrutinib or chemoimmunotherapy: a real-world retrospective study publication-title: Clin Ther contributor: fullname: Huang – volume: 19 start-page: 1218 year: 2021 end-page: 1230 ident: bib0031 article-title: NCCN guidelines® insights: B-cell lymphomas, version 5.2021 publication-title: J Natl Compr Cancer Netw JNCCN contributor: fullname: Chang – volume: 367 start-page: 520 year: 2012 end-page: 531 ident: bib0003 article-title: Treatment of older patients with mantle-cell lymphoma publication-title: N Engl J Med contributor: fullname: Hermine – volume: 4 start-page: 1491 year: 2018 end-page: 1500 ident: bib0012 article-title: Ibrutinib-associated atrial fibrillation publication-title: JACC Clin Electrophysiol contributor: fullname: Shah – volume: 25 start-page: 386 year: 2019 end-page: 393 ident: bib0015 article-title: BTK inhibitors: present and future publication-title: Cancer J Sudbury Mass contributor: fullname: Burger – volume: 13 start-page: 67 year: 2023 end-page: 76 ident: bib0017 article-title: Zanubrutinib in mantle cell lymphoma management: a comprehensive review publication-title: Blood Lymphat Cancer Targets Ther contributor: fullname: McBride – volume: 96 start-page: 1374 year: 2021 end-page: 1384 ident: bib0005 article-title: Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era publication-title: Am J Hematol contributor: fullname: Goyal – volume: 64 start-page: 1752 year: 2023 end-page: 1770 ident: bib0030 article-title: Assessing unmet need among elderly medicare beneficiaries with mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs publication-title: Leuk Lymphoma contributor: fullname: Ryland – volume: 369 start-page: 507 year: 2013 end-page: 516 ident: bib0007 article-title: Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma publication-title: N Engl J Med contributor: fullname: Martin – volume: 9 start-page: 80 year: 2016 ident: bib0014 article-title: Second-generation inhibitors of Bruton tyrosine kinase publication-title: J Hematol OncolJ Hematol Oncol contributor: fullname: Liu – volume: 12 start-page: 894 year: 2021 end-page: 901 ident: bib0028 article-title: A medicare database analysis of practice patterns in patients with mantle cell lymphoma publication-title: J Geriatr Oncol contributor: fullname: Morrison – volume: 26 start-page: 4216 year: 2020 end-page: 4224 ident: bib0009 article-title: Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton's tyrosine kinase publication-title: Clin Cancer Res Off J Am Assoc Cancer Res contributor: fullname: Zou – volume: 113 start-page: 791 year: 2008 end-page: 798 ident: bib0002 article-title: Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004 publication-title: Cancer contributor: fullname: Fang – volume: 192 start-page: 737 year: 2021 end-page: 746 ident: bib0004 article-title: Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study publication-title: Br J Haematol contributor: fullname: Andorsky – volume: 126 start-page: 739 year: 2015 end-page: 745 ident: bib0013 article-title: Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results publication-title: Blood contributor: fullname: Martin – volume: 8 start-page: 3803 year: 2019 end-page: 3810 ident: bib0024 article-title: Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States publication-title: Cancer Med contributor: fullname: Davis – volume: 12 start-page: 8003 year: 2019 end-page: 8014 ident: bib0011 article-title: Evaluating acalabrutinib in the treatment of mantle cell lymphoma: design, development, and place in therapy publication-title: OncoTargets Ther contributor: fullname: Devata – volume: 11 start-page: 764 year: 2021 ident: bib0022 article-title: Non-covalent BTK inhibitors—the new BTKids on the block for B-cell malignancies publication-title: J Pers Med contributor: fullname: Cheah – volume: 27 start-page: 1209 year: 2009 end-page: 1213 ident: bib0006 article-title: Outcome of deferred initial therapy in mantle-cell lymphoma publication-title: J Clin Oncol Off J Am Soc Clin Oncol contributor: fullname: Christos – volume: 60 start-page: 955 year: 2019 end-page: 963 ident: bib0026 article-title: Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States publication-title: Leuk Lymphoma contributor: fullname: Mato – volume: 183 start-page: 578 issue: 4 year: 2018 ident: 10.1016/j.clml.2024.05.023_bib0020 article-title: Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib publication-title: Br J Haematol doi: 10.1111/bjh.15567 contributor: fullname: Jain – volume: 192 start-page: 737 issue: 4 year: 2021 ident: 10.1016/j.clml.2024.05.023_bib0004 article-title: Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study publication-title: Br J Haematol doi: 10.1111/bjh.16922 contributor: fullname: Sharman – volume: 12 start-page: 894 issue: 6 year: 2021 ident: 10.1016/j.clml.2024.05.023_bib0028 article-title: A medicare database analysis of practice patterns in patients with mantle cell lymphoma publication-title: J Geriatr Oncol doi: 10.1016/j.jgo.2020.12.013 contributor: fullname: Weaver – volume: 96 start-page: E137 issue: 5 year: 2021 ident: 10.1016/j.clml.2024.05.023_bib0034 article-title: Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib publication-title: Am J Hematol doi: 10.1002/ajh.26109 contributor: fullname: Jain – volume: 202 start-page: 749 issue: 4 year: 2023 ident: 10.1016/j.clml.2024.05.023_bib0035 article-title: Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study publication-title: Br J Haematol doi: 10.1111/bjh.18519 contributor: fullname: Hess – volume: 387 start-page: 770 issue: 10020 year: 2016 ident: 10.1016/j.clml.2024.05.023_bib0008 article-title: Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study publication-title: Lancet Lond Engl doi: 10.1016/S0140-6736(15)00667-4 contributor: fullname: Dreyling – volume: 25 start-page: 386 issue: 6 year: 2019 ident: 10.1016/j.clml.2024.05.023_bib0015 article-title: BTK inhibitors: present and future publication-title: Cancer J Sudbury Mass doi: 10.1097/PPO.0000000000000412 contributor: fullname: Burger – volume: 12 start-page: 8003 year: 2019 ident: 10.1016/j.clml.2024.05.023_bib0011 article-title: Evaluating acalabrutinib in the treatment of mantle cell lymphoma: design, development, and place in therapy publication-title: OncoTargets Ther doi: 10.2147/OTT.S155778 contributor: fullname: Girard – ident: 10.1016/j.clml.2024.05.023_bib0001 – volume: 62 start-page: 1325 issue: 6 year: 2021 ident: 10.1016/j.clml.2024.05.023_bib0029 article-title: Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma publication-title: Leuk Lymphoma doi: 10.1080/10428194.2021.1919662 contributor: fullname: Goyal – volume: 126 start-page: 739 issue: 6 year: 2015 ident: 10.1016/j.clml.2024.05.023_bib0013 article-title: Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results publication-title: Blood doi: 10.1182/blood-2015-03-635326 contributor: fullname: Wang – volume: 13 start-page: 67 year: 2023 ident: 10.1016/j.clml.2024.05.023_bib0017 article-title: Zanubrutinib in mantle cell lymphoma management: a comprehensive review publication-title: Blood Lymphat Cancer Targets Ther doi: 10.2147/BLCTT.S426588 contributor: fullname: Alsuhebany – volume: 19 start-page: 1218 issue: 11 year: 2021 ident: 10.1016/j.clml.2024.05.023_bib0031 article-title: NCCN guidelines® insights: B-cell lymphomas, version 5.2021 publication-title: J Natl Compr Cancer Netw JNCCN doi: 10.6004/jnccn.2021.0054 contributor: fullname: Zelenetz – volume: 43 start-page: 1285 issue: 8 year: 2021 ident: 10.1016/j.clml.2024.05.023_bib0025 article-title: Treatment patterns among patients with mantle cell lymphoma and comparison of healthcare resource utilization and costs among relapsed/refractory patients treated with ibrutinib or chemoimmunotherapy: a real-world retrospective study publication-title: Clin Ther doi: 10.1016/j.clinthera.2021.06.012 contributor: fullname: Ghosh – volume: 24 start-page: 1189 issue: 9 year: 2022 ident: 10.1016/j.clml.2024.05.023_bib0021 article-title: CAR T-cell therapy in the older person: indications and risks publication-title: Curr Oncol Rep doi: 10.1007/s11912-022-01272-6 contributor: fullname: Shouse – ident: 10.1016/j.clml.2024.05.023_bib0032 – volume: 27 start-page: 1209 issue: 8 year: 2009 ident: 10.1016/j.clml.2024.05.023_bib0006 article-title: Outcome of deferred initial therapy in mantle-cell lymphoma publication-title: J Clin Oncol Off J Am Soc Clin Oncol doi: 10.1200/JCO.2008.19.6121 contributor: fullname: Martin – volume: 8 start-page: 6860 issue: 16 year: 2019 ident: 10.1016/j.clml.2024.05.023_bib0019 article-title: Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience publication-title: Cancer Med doi: 10.1002/cam4.2565 contributor: fullname: Jeon – volume: 397 start-page: 892 issue: 10277 year: 2021 ident: 10.1016/j.clml.2024.05.023_bib0023 article-title: Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study publication-title: Lancet Lond Engl doi: 10.1016/S0140-6736(21)00224-5 contributor: fullname: Mato – volume: 26 start-page: 4216 issue: 16 year: 2020 ident: 10.1016/j.clml.2024.05.023_bib0009 article-title: Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton's tyrosine kinase publication-title: Clin Cancer Res Off J Am Assoc Cancer Res doi: 10.1158/1078-0432.CCR-19-3703 contributor: fullname: Song – volume: 96 start-page: 1374 issue: 11 year: 2021 ident: 10.1016/j.clml.2024.05.023_bib0005 article-title: Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era publication-title: Am J Hematol doi: 10.1002/ajh.26306 contributor: fullname: Karmali – volume: 367 start-page: 520 issue: 6 year: 2012 ident: 10.1016/j.clml.2024.05.023_bib0003 article-title: Treatment of older patients with mantle-cell lymphoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1200920 contributor: fullname: Kluin-Nelemans – volume: 9 start-page: 80 issue: 1 year: 2016 ident: 10.1016/j.clml.2024.05.023_bib0014 article-title: Second-generation inhibitors of Bruton tyrosine kinase publication-title: J Hematol OncolJ Hematol Oncol doi: 10.1186/s13045-016-0313-y contributor: fullname: Wu – volume: 6 start-page: 4122 issue: 14 year: 2022 ident: 10.1016/j.clml.2024.05.023_bib0033 article-title: Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma publication-title: Blood Adv doi: 10.1182/bloodadvances.2022007247 contributor: fullname: Narkhede – volume: 369 start-page: 507 issue: 6 year: 2013 ident: 10.1016/j.clml.2024.05.023_bib0007 article-title: Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1306220 contributor: fullname: Wang – volume: 113 start-page: 791 issue: 4 year: 2008 ident: 10.1016/j.clml.2024.05.023_bib0002 article-title: Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004 publication-title: Cancer doi: 10.1002/cncr.23608 contributor: fullname: Zhou – volume: 64 start-page: 1752 issue: 11 year: 2023 ident: 10.1016/j.clml.2024.05.023_bib0030 article-title: Assessing unmet need among elderly medicare beneficiaries with mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs publication-title: Leuk Lymphoma doi: 10.1080/10428194.2023.2234525 contributor: fullname: Squires – volume: 41 start-page: 927 issue: 2 year: 2021 ident: 10.1016/j.clml.2024.05.023_bib0027 article-title: Adverse events and economic burden among patients receiving systemic treatment for mantle cell lymphoma: a real-world retrospective cohort study publication-title: Anticancer Res doi: 10.21873/anticanres.14846 contributor: fullname: Kabadi – volume: 8 start-page: 3803 issue: 8 year: 2019 ident: 10.1016/j.clml.2024.05.023_bib0024 article-title: Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States publication-title: Cancer Med doi: 10.1002/cam4.2268 contributor: fullname: Kabadi – volume: 33 start-page: 2762 issue: 11 year: 2019 ident: 10.1016/j.clml.2024.05.023_bib0018 article-title: Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma publication-title: Leukemia doi: 10.1038/s41375-019-0575-9 contributor: fullname: Wang – volume: 11 start-page: 764 issue: 8 year: 2021 ident: 10.1016/j.clml.2024.05.023_bib0022 article-title: Non-covalent BTK inhibitors—the new BTKids on the block for B-cell malignancies publication-title: J Pers Med doi: 10.3390/jpm11080764 contributor: fullname: Lewis – volume: 4 start-page: 1491 issue: 12 year: 2018 ident: 10.1016/j.clml.2024.05.023_bib0012 article-title: Ibrutinib-associated atrial fibrillation publication-title: JACC Clin Electrophysiol doi: 10.1016/j.jacep.2018.06.004 contributor: fullname: Ganatra – volume: 12 start-page: 1328 issue: 5 year: 2020 ident: 10.1016/j.clml.2024.05.023_bib0016 article-title: Ibrutinib resistance mechanisms and treatment strategies for B-cell lymphomas publication-title: Cancers doi: 10.3390/cancers12051328 contributor: fullname: George – volume: 60 start-page: 955 issue: 4 year: 2019 ident: 10.1016/j.clml.2024.05.023_bib0026 article-title: Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States publication-title: Leuk Lymphoma doi: 10.1080/10428194.2018.1509320 contributor: fullname: Goyal – volume: 133 start-page: 2570 issue: 24 year: 2019 ident: 10.1016/j.clml.2024.05.023_bib0010 article-title: Acalabrutinib for mantle cell lymphoma publication-title: Blood doi: 10.1182/blood.2019852368 contributor: fullname: Witzig |
SSID | ssj0070019 |
Score | 2.4054272 |
Snippet | While covalent Bruton's tyrosine kinase inhibitors (cBTKis) have become a standard of care treatment for relapsed/refractory mantle cell lymphoma (R/R MCL),... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | e350 |
SubjectTerms | Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors Aged Aged, 80 and over Cost of Illness Costs Female Humans Ibrutinib Lymphoma, Mantle-Cell - drug therapy Lymphoma, Mantle-Cell - economics Lymphoma, Mantle-Cell - mortality Lymphoma, Mantle-Cell - therapy Male Mantle cell lymphoma Medicare Protein Kinase Inhibitors - economics Protein Kinase Inhibitors - therapeutic use Retrospective Studies Unmet need |
Title | Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis |
URI | https://dx.doi.org/10.1016/j.clml.2024.05.023 https://www.ncbi.nlm.nih.gov/pubmed/39034204 https://www.proquest.com/docview/3083215792 |
Volume | 24 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe6TUK8IL4pXzISb12mxE6W5LErQYMxNNEi-hY5yUV0JB1i66T-99z5I-kmhgCJl8i18mH5fj2fz7-7Y-y1qNNQqlR5URJLLyyCxEtSbKVVgCpZBSC0w-1wGn-cJ2-yMBsMXDWBvu-_Shr7UNYUOfsX0u5eih3YRpnjFaWO1z-S-ye0_DxLkelI5Cc6i6Yxmacr1A6XOs-_PjlwockjE9EwGuvyQxlV727Wo-PJB3p6oQPhKN8TcWaxX78bjdUvmrp-MDtanG_auRMXcNmsES5nrTZR2zU02NRfbWD1DdpFtyhMiZG8WTWgiyA6IeaHPcKi0mN96NrasTKPXBjjFZaaWUhUi_NxoL42xv9N1NFNT4cIO86cdb-5EJwrDFGqy-uJfZO91ql0E5btoOtvKGiQ9k5wP5M9CH65lhi3xule2bR0RiVCneLVREdfy9E9pVHQIIiRi435FtsRqPlQ8e6M32Xz9844oFN-2pF1o7ZxXIZyeP1LN9lKN-2FtE00u8vu2M0MHxsU3mMDWN5nt44tXeMBu-zByDswcgfGXe6guMtRkNwBkRsgcg1EboHIEYjcAZH3QOQWiJyAyA0QH7LPb7PZ5NCzhT68Usj4wisCWUEK2rtWA0AYQKQCWcZVIsr9VEUqgago0BQtfYh9ofw4hUJVdSLqGhdo-YhtL8-W8ITxNCanQCQLqMowUVVSxKoIy7KKS-KYyCEbuSnNv5t8LrkjOp7mJICcBJD7UY4CGLLIzXpuLVJjaeYIkt8-98qJKEd1TWdwagk4Lbn0qTRYFKdiyB4b2XXjkCnl4_TDp__41Wfsdv-3ec62L36s4AXbOq9WLy0MfwKjlMUY |
link.rule.ids | 315,782,786,27933,27934 |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Real-World+Treatment+Patterns%2C+Survival%2C+and+Economic+Burden+Among+Elderly+MCL+Patients+Previously+Treated+With+cBTKis&rft.jtitle=Clinical+lymphoma%2C+myeloma+and+leukemia&rft.au=Squires%2C+Patrick&rft.au=Puckett%2C+Justin&rft.au=Ryland%2C+Katherine+Elizabeth&rft.au=Kamal-Bahl%2C+Sachin&rft.date=2024-10-01&rft.pub=Elsevier+Inc&rft.issn=2152-2650&rft.volume=24&rft.issue=10&rft.spage=e350&rft.epage=e358.e1&rft_id=info:doi/10.1016%2Fj.clml.2024.05.023&rft.externalDocID=S215226502400226X |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2152-2650&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2152-2650&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2152-2650&client=summon |